SCHEMBL704543

SCHEMBL704543

O=[C]c1ccc(C(=O)OCc2ccccc2)cc1

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 4/20 0.71
TDP1 Q9NUW8 4/20 0.71
SLC6A2 P23975 1/20 0.71
SLC6A3 Q01959 1/20 0.71
LMNA P02545 3/20 0.70
ALDH1A1 P00352 6/20 0.60
MAPT P10636 4/20 0.60
HPGD P15428 1/20 0.60
MEN1 O00255 1/20 0.56
RAB9A P51151 4/20 0.55
GAA P10253 1/20 0.55
NPC1 O15118 2/20 0.52
SMN1; SMN2 Q16637 1/20 0.52
ESR1 P03372 1/20 0.51
ESR2 Q92731 1/20 0.51
L3MBTL1 Q9Y468 2/20 0.49
HSP90AA1 P07900 1/20 0.48
NR4A1 P22736 1/20 0.47
NR4A2 P43354 1/20 0.47
NR4A3 Q92570 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL312287 0.88 KMT2A (0.92) KMT2ATDP1SLC6A2SLC6A3LMNA
SCHEMBL2682737 0.85 KMT2A (0.69) KMT2ATDP1SLC6A2SLC6A3LMNA
SCHEMBL17769820 0.85 KMT2A (0.69) KMT2ATDP1SLC6A2SLC6A3LMNA
SCHEMBL692401 0.85 KMT2A (0.55) KMT2ATDP1SLC6A2SLC6A3LMNA
SCHEMBL9100113 0.84 ESR1 (0.69) KMT2ATDP1SLC6A2SLC6A3LMNA
Benzyl Benzoate SCHEMBL901058 0.84 KMT2A (1.00) KMT2ATDP1SLC6A2SLC6A3LMNA
Benzyl Benzoate SCHEMBL8010992 0.84 KMT2A (1.00) KMT2ATDP1SLC6A2SLC6A3LMNA
Benzyl Benzoate SCHEMBL3038 0.84 KMT2A (1.00) KMT2ATDP1SLC6A2SLC6A3LMNA
SCHEMBL9099807 0.83 TDP1 (0.65) KMT2ATDP1SLC6A2SLC6A3LMNA
SCHEMBL27578 0.82 LMNA (1.00) KMT2ATDP1SLC6A2SLC6A3LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 597 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-1094035-A Carboxylic acid derivative contains pharmaceutical composition of these compounds and preparation method thereof THOMAE GMBH DR K (DE) 1994-10-26 CN claimed
US-11850237-B2 Compounds and methods for treating influenza ROMARK LABORATORIES L.C. (US) 2023-12-26 US disclosed
EP-2445349-B1 COMPOUNDS AND METHODS FOR TREATING INFLUENZA ROMARK LABORATORIES LC (US) 2022-02-09 EP disclosed
EP-3895706-A1 THIAZOLINIDE COMPOUNDS FOR TREATING NON-INFLUENZA VIRAL INFECTIONS Romark Laboratories, L.C. (US) 2021-10-20 EP disclosed
US-20210177809-A1 COMPOUNDS AND METHODS FOR TREATING INFLUENZA ROMARK LABORATORIES L.C. (US) 2021-06-17 US disclosed
US-10912768-B2 Compounds and methods for treating influenza ROMARK LABORATORIES L.C. (US) 2021-02-09 US disclosed
US-RE47786-E1 Haloalkyl heteroaryl benzamide compounds ROMARK LABORATORIES L.C. (US) 2019-12-31 US disclosed
US-20190307730-A1 COMPOUNDS AND METHODS FOR TREATING INFLUENZA ROMARK LABORATORIES L.C. (US) 2019-10-10 US disclosed
US-10363243-B2 Compounds and methods for treating influenza ROMARK LABORATORIES L.C. (US) 2019-07-30 US disclosed
EP-1805158-B1 SULFONYL-SUBSTITUTED BICYCLIC COMPOUNDS AS MODULATORS OF PPAR KALYPSYS INC (US) 2018-06-27 EP disclosed
EP-0180188-B1 A COMPOSITION FOR INCREASING THE ANTI-CANCER ACTIVITY OF AN ANTI-CANCER COMPOUND OTSUKA PHARMACEUTICAL CO., LTD. (JP) 1992-04-15 EP disclosed
EP-0180897-B1 5-FLUOROURACIL DERIVATIVES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 1991-08-07 EP disclosed
EP-0436902-A1 5-Fluorouracil derivatives OTSUKA PHARMACEUTICAL CO., LTD. (JP) 1991-07-17 EP disclosed
EP-0432694-A2 Aminoalcohols F. HOFFMANN-LA ROCHE AG (CH) 1991-06-19 EP disclosed
US-4983609-A Anticancer agents OTSUKA PHARMACEUTICAL (JP) 1991-01-08 US disclosed
EP-0346847-A2 Amino acid derivatives F. HOFFMANN-LA ROCHE AG (CH) 1989-12-20 EP disclosed
US-4864021-A ANTICARCINOGENIC AGENTS, ANTITUMOR AGENTS OTSUKA PHARMACEUTICAL CO., LTD. (JP) 1989-09-05 US disclosed
EP-0323441-A2 5-Fluorouracil derivatives OTSUKA PHARMACEUTICAL CO., LTD. (JP) 1989-07-05 EP disclosed
EP-0180897-A2 5-Fluorouracil derivatives OTSUKA PHARMACEUTICAL CO., LTD. (JP) 1986-05-14 EP disclosed
EP-0180188-A2 A composition for increasing the anti-cancer activity of an anti-cancer compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 1986-05-07 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10912768-B2 Compounds and methods for treating influenza HIF1AN, HAVCR2, NEU1 KMT2A 2029/4885TDP1 4414/4885SLC6A2 2749/4885
US-20210177809-A1 COMPOUNDS AND METHODS FOR TREATING INFLUENZA HIF1AN, HAVCR2, NEU1 KMT2A 2029/4885TDP1 4414/4885SLC6A2 2749/4885
US-20190307730-A1 COMPOUNDS AND METHODS FOR TREATING INFLUENZA HIF1AN, HAVCR2, NEU1 KMT2A 2029/4885TDP1 4414/4885SLC6A2 2749/4885
US-11850237-B2 Compounds and methods for treating influenza HIF1AN, HAVCR2, NEU1 KMT2A 2029/4885TDP1 4414/4885SLC6A2 2749/4885
US-10363243-B2 Compounds and methods for treating influenza HIF1AN, HAVCR2, NEU1 KMT2A 2029/4885TDP1 4414/4885SLC6A2 2749/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.